drugset / Trial / NCT02561130

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

NCT02561130

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising Forxiga, metformin, basal insulin glargine and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.

Timeline

Start
2015-12
Primary completion
2017-07
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Forxiga Unknown 10 mg Oral
Subject Metformin Small molecule 1 g Oral
Subject insulin glargine Protein / enzyme biologic Subcutaneous